Loading
A phase 1 trial of ST-01156 run by SEED Therapeutics, Inc., now recruiting.
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies is a phase 1 interventional study registered as NCT07197554 by SEED Therapeutics, Inc., with 171 participants planned, started 2025-12-01. Conditions recorded: Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC) and Biliary Tract Cancer (BTC). Interventions recorded: ST-01156.
Shares Hepatocellular carcinoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Hepatocellular carcinoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Hepatocellular carcinoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Hepatocellular carcinoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Hepatocellular carcinoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Hepatocellular carcinoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Hepatocellular carcinoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/